Dimension Therapeutics, Inc. (NASDAQ:DMTX) Releases Quarterly Earnings Results
Dimension Therapeutics, Inc. (NASDAQ:DMTX) posted its quarterly earnings results on Tuesday. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.49), Bloomberg Earnings reports. The company had revenue of $4.37 million for the quarter. Dimension Therapeutics had a negative return on equity of 80.04% and a negative net margin of 412.27%.
Dimension Therapeutics (NASDAQ:DMTX) remained flat at $1.25 during trading on Wednesday. The company had a trading volume of 88,437 shares. The stock’s 50 day moving average price is $1.37 and its 200 day moving average price is $1.73. The stock’s market cap is $31.30 million. Dimension Therapeutics has a 12 month low of $1.05 and a 12 month high of $9.98.
Several research analysts have issued reports on DMTX shares. Canaccord Genuity dropped their price target on Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, June 28th. Zacks Investment Research raised Dimension Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Tuesday, May 2nd. Cantor Fitzgerald set a $3.00 price target on Dimension Therapeutics and gave the company a “hold” rating in a report on Saturday, June 10th. Finally, Citigroup Inc. cut Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 price target on the stock. in a report on Friday, May 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $5.88.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.